Jacobs Levy Equity Management, Inc Satsuma Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $325,920 - $490,058	-78,535 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $14,559 - $22,994	-3,207 Reduced 3.92%	78,535 $366,000
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $444,739 - $671,741	-92,654 Reduced 53.13%	81,742 $576,000
Q1 2021 May 17, 2021	SELL	$4.57 - $7.18 $97,135 - $152,610	-21,255 Reduced 10.86%	174,396 $1.03 Million
Q4 2020 Feb 16, 2021	BUY	$3.56 - $5.09 $696,517 - $995,863	195,651 New	195,651 $902,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.